<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281918</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454560</org_study_id>
    <secondary_id>GCLLSG-CLL-8</secondary_id>
    <secondary_id>EU-20560</secondary_id>
    <secondary_id>ML17102</secondary_id>
    <nct_id>NCT00281918</nct_id>
  </id_info>
  <brief_title>Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia</brief_title>
  <acronym>CLL-8</acronym>
  <official_title>Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to
      see how well they work compared to fludarabine and cyclophosphamide in treating patients with
      B-cell chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
    <description>Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final Analysis: Time to Progression-free Survival Event</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>Progression-free survival was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
    <description>Event-free survival (EFS) was defined as the time between randomization and the date of disease progression, relapse, start of new CLL treatment or death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
    <description>Overall survival (OS) was defined as the time between randomization and the date of death due to any cause. Median OS was not reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).</measure>
    <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
    <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death. Median DFS was not reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Analysis: Time to Overall Survival Event</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>Overall survival (OS) was defined as the time between randomization and the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Analysis: Time to Event-free Survival Event</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>Event-free survival was defined as the time between randomization and the date of disease progression, relapse, start of new Chronic Lymphocytic Leukemia treatment or death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Analysis: Duration of Response</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>Duration of response was defined as the time from the first documented Complete Response, Partial Response to disease progression or death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. Partial response is defined as a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL)</measure>
    <time_frame>Median observation time was approximately 66.4 months</time_frame>
    <description>The time from randomization to the start of a new treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">817</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine+Cyclophosphamide+Rituximab (FCR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine+Cyclophosphamide (FC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Fludarabine+Cyclophosphamide+Rituximab (FCR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Fludarabine+Cyclophosphamide+Rituximab (FCR)</arm_group_label>
    <arm_group_label>Fludarabine+Cyclophosphamide (FC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Fludarabine+Cyclophosphamide+Rituximab (FCR)</arm_group_label>
    <arm_group_label>Fludarabine+Cyclophosphamide (FC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosed B-cell chronic lymphocytic leukemia (CLL) defined by the National Cancer
             Institute (NCI) Working Group criteria

          -  Meets 1 of the following criteria:

               -  Binet stage C disease

               -  Binet stage B disease AND â‰¥ 1 of the following signs or symptoms*:

                    -  B symptoms (night sweats, weight loss â‰¥ 10% within the previous 6 months,
                       fevers &gt; 38Â°C or 100.4Â°F for â‰¥ 2 weeks without evidence of infection), or
                       constitutional symptoms (fatigue)

                    -  Continuous progression (doubling of peripheral lymphocyte count within the
                       past 6 months and absolute lymphocyte count &gt; 50 G/I)

                    -  Evidence of progressive marrow failure as manifested by the
                       development/worsening of anemia and/or thrombocytopenia

                    -  Massive, progressive or painful splenomegaly or hypersplenism

                    -  Massive lymph nodes or lymph node clusters (&gt; 10 cm in longest diameter),
                       danger of organ complications through large lymphoma (e.g., vascular
                       compression or tracheal narrowing), or progressive lymphadenopathy

                    -  Occurrence of symptomatic hyperviscosity problems at leukocyte counts &gt; 200
                       G/I (symptomatic leukostasis) NOTE: * Marked hypogammaglobulinemia or the
                       development of a monoclonal protein in the absence of any of the above
                       criteria for active disease is not sufficient for eligibility

          -  No Binet stage A disease

          -  No transformation to an aggressive B-cell malignancy (e.g., diffuse large cell
             lymphoma, Richter's syndrome, or prolymphocytic leukemia)

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Cumulative Illness Rating Scale (CIRS) score &gt; 6

          -  Life expectancy &gt; 6 months

          -  Bilirubin â‰¤ 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase and transaminases â‰¤ 2 times ULN

          -  Creatinine clearance â‰¥ 70 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 2 months after study
             treatment

          -  No known hypersensitivity with anaphylactic reaction to humanized monoclonal
             antibodies or any of the study drugs

          -  No cerebral dysfunction that precludes chemotherapy

          -  No active bacterial, viral, or fungal infection

          -  No clinically significant autoimmune cytopenia or Coombs-positive hemolytic anemia

          -  No other active malignancy requiring concurrent treatment except basal cell carcinoma
             or tumors treated curatively by surgery

          -  No medical or psychological condition that would preclude study therapy

          -  No concurrent disease that requires prolonged (&gt; 1 month) therapy involving
             glucocorticoids

        PRIOR CONCURRENT THERAPY:

          -  No previous treatment of CLL by chemotherapy, radiotherapy, or immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hallek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medizinische Universitaetsklinik I at the University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Institute for Cancer Research at Westmead Hospital</name>
      <address>
        <city>Westmead - Wentworthville</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanuschkrankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rudolfinerhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1190</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire De Mont-Godinne</name>
      <address>
        <city>Mont-Godinne Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital in Pilsen - Lochotin</name>
      <address>
        <city>Pilsen-Lochotin</city>
        <zip>30460</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medical Clinic of Charles University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen County Herlev University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Fur Hamatologie und Onkologie Ahaus</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie</name>
      <address>
        <city>Ansbach</city>
        <zip>91522</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>DOH-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humaine - Clinic</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95448</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33602</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Bietigheim</name>
      <address>
        <city>Bietigheim</city>
        <zip>D-74321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop gGmbH</name>
      <address>
        <city>Bottrop</city>
        <zip>D-46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>D-28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Burglengenfeld</name>
      <address>
        <city>Burglengenfeld</city>
        <zip>D-93133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis at Facharzt fuer Innere Medizin</name>
      <address>
        <city>Coesfeld</city>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Fuer Haematologie Internistische Onkologie</name>
      <address>
        <city>Cologne</city>
        <zip>D-50677</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Cottbus</city>
        <zip>D-03046</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis - Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Benrath</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40593</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Georg Klinikum Eisenach GmbH</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>99012</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistiche Praxis</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunkt Praxis</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Eschweiler</city>
        <zip>DOH-52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Essen Werden</name>
      <address>
        <city>Essen</city>
        <zip>D-45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>D-73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Forchheim</name>
      <address>
        <city>Forchheim</city>
        <zip>91301</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>D-15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main - Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis - Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Garmisch - Partenkirchen GmbH</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>D-82467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Gerlingen</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Fuer Innere Medizin, Hematologie Und Onkologie</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Halle</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>D-06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Hamm - Klinik Knappenstrasse</name>
      <address>
        <city>Hamm</city>
        <zip>D-59071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <zip>DOH-59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Siloah - Medizinische Klinik II</name>
      <address>
        <city>Hannover</city>
        <zip>D-30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital at Ruhr University Bochum</name>
      <address>
        <city>Herne</city>
        <zip>D-44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatklinik Dr. R. Schindlbeck GmbH &amp; Co. KG</name>
      <address>
        <city>Herrsching</city>
        <zip>D-82211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>D-66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Innere Medizin</name>
      <address>
        <city>Jena</city>
        <zip>D-07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius-Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>D-34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten Oberallgaeu</name>
      <address>
        <city>Kempten</city>
        <zip>D-87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Haematologie und Onkologie</name>
      <address>
        <city>Koblenz</city>
        <zip>D-56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH</name>
      <address>
        <city>Koblez</city>
        <zip>D-56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Onkologische Praxis - Kronach</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis - Leer</name>
      <address>
        <city>Leer</city>
        <zip>D-26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum &quot;St. Georg&quot; Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe - Lemgo</name>
      <address>
        <city>Lemgo</city>
        <zip>D-32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Loerrach</name>
      <address>
        <city>Loerrach</city>
        <zip>D-79539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis - Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Magdeburg - Altstadt</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf GmbH</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>D-41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologie/Onkologie Praxisgemeinschaft - Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>D-81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologisch - Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen - Harlaching</name>
      <address>
        <city>Munich</city>
        <zip>D-81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologische Schwerpunktpraxis</name>
      <address>
        <city>Munich</city>
        <zip>D-81679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dr. Schmidt</name>
      <address>
        <city>Neunkirchen</city>
        <zip>D-66538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Haematologie und Interne Onkologie</name>
      <address>
        <city>Norderstedt</city>
        <zip>22844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg - Klinikum Nord</name>
      <address>
        <city>Nuernberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis - Oberhausen</name>
      <address>
        <city>Oberhausen</city>
        <zip>D-46045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Offenbach</name>
      <address>
        <city>Offenbach</city>
        <zip>D-63065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>D-26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>D-26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Pasewalk</name>
      <address>
        <city>Pasewalk</city>
        <zip>17309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital Complex</name>
      <address>
        <city>Pforzheim</city>
        <zip>D-75178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst Von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <zip>D-14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brueder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>D-18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritasklinik St. Theresia</name>
      <address>
        <city>Saarbrucken</city>
        <zip>D-66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordwestkrankenhaus Sanderbusch</name>
      <address>
        <city>Sanderbusch</city>
        <zip>26452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien - Krankenhaus Siegen GMBH</name>
      <address>
        <city>Siegen</city>
        <zip>D-57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologische Praxis</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fuer Onkologie - Katharinenhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KKH Torgau</name>
      <address>
        <city>Torgau</city>
        <zip>04860</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis - Trier</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Mutterhaus der Borromaerinnen</name>
      <address>
        <city>Trier</city>
        <zip>D-54219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Fuer Internistische Haematologie / Onkologie</name>
      <address>
        <city>Troisdorf</city>
        <zip>53840</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital Complex</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>D-78045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fur Innere Medizin - Wanzleben</name>
      <address>
        <city>Wanzleben</city>
        <zip>39164</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologische Praxis</name>
      <address>
        <city>Weiden</city>
        <zip>D-92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Hamatologie/Onkologie - Wesel</name>
      <address>
        <city>Wesel</city>
        <zip>46483</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken St. Antonius</name>
      <address>
        <city>Wuppertal 2</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologisch - Onkologische Praxis Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BNAI Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverview Cancer Care Medical Associates, PC</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Hospital</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A. Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele Del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perugia Regional Cancer Center</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canterbury Health Laboratories</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del La Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.roche-trials.com/studyResultGet.action?studyResultNumber=ML17102</url>
    <description>Clinical Study Report Synopsis</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <results_first_submitted>December 21, 2009</results_first_submitted>
  <results_first_submitted_qc>March 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2011</results_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine+Cyclophosphamide (FC)</title>
          <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
          <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="409">Informed consent unavailable for 2 patients at time of analysis; intent-to-treat population was 407.</participants>
                <participants group_id="P2" count="408">Informed consent unavailable for 5 patients at time of analysis; intent-to-treat population was 403.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population; Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="398"/>
                <participants group_id="P2" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267">Completed all 6 cycles of study medication.</participants>
                <participants group_id="P2" count="300">Completed all 6 cycles of study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine+Cyclophosphamide (FC)</title>
          <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
          <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="407"/>
            <count group_id="B2" value="403"/>
            <count group_id="B3" value="810"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="8.55"/>
                    <measurement group_id="B2" value="59.6" spread="8.70"/>
                    <measurement group_id="B3" value="59.5" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.</description>
        <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
        <population>The Intent-to-treat (ITT) population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival (PFS) was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.</description>
          <population>The Intent-to-treat (ITT) population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="981.0" lower_limit="1" upper_limit="1343"/>
                    <measurement group_id="O2" value="1212.0" lower_limit="1" upper_limit="1372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS)</title>
        <description>Event-free survival (EFS) was defined as the time between randomization and the date of disease progression, relapse, start of new CLL treatment or death by any cause.</description>
        <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
        <population>The ITT population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS)</title>
          <description>Event-free survival (EFS) was defined as the time between randomization and the date of disease progression, relapse, start of new CLL treatment or death by any cause.</description>
          <population>The ITT population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="947.0" lower_limit="1" upper_limit="1343"/>
                    <measurement group_id="O2" value="1212.0" lower_limit="1" upper_limit="1372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) was defined as the time between randomization and the date of death due to any cause. Median OS was not reached.</description>
        <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
        <population>The ITT population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) was defined as the time between randomization and the date of death due to any cause. Median OS was not reached.</description>
          <population>The ITT population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum number of days to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="83" upper_limit="90"/>
                    <measurement group_id="O2" value="4" lower_limit="89" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum number of days to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1373"/>
                    <measurement group_id="O2" value="1372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0427</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).</title>
        <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death. Median DFS was not reached.</description>
        <time_frame>Median observation time at time of analysis was approximately 21 months</time_frame>
        <population>The ITT population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).</title>
          <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death. Median DFS was not reached.</description>
          <population>The ITT population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not. Informed consent was unavailable at the time of analysis for 2 patients in the FC group and 5 patients in the FCR group. ITT population: FC = 407; FCR = 403.</population>
          <units>Days to an event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum number of days to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="91" lower_limit="939" upper_limit="9999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum number of days to an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1164"/>
                    <measurement group_id="O2" value="1226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7882</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Final Analysis: Time to Progression-free Survival Event</title>
        <description>Progression-free survival was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Participants from the Intent-to-treat population, that included all randomized participants, with PFS events.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Time to Progression-free Survival Event</title>
          <description>Progression-free survival was defined as the time between randomization and the date of first documented disease progression, relapse or death by any cause, whichever came first.</description>
          <population>Participants from the Intent-to-treat population, that included all randomized participants, with PFS events.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="998.0" lower_limit="886" upper_limit="1129"/>
                    <measurement group_id="O2" value="1703.0" lower_limit="1543" upper_limit="1853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Analysis: Time to Overall Survival Event</title>
        <description>Overall survival (OS) was defined as the time between randomization and the date of death due to any cause.</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Participants from the Intent-to-treat population, that included all randomized participants who died.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Time to Overall Survival Event</title>
          <description>Overall survival (OS) was defined as the time between randomization and the date of death due to any cause.</description>
          <population>Participants from the Intent-to-treat population, that included all randomized participants who died.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2613.0" lower_limit="2354">Upper limit of the 95% confidence interval has not been reached.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="2745">Median time to event and upper limit of the 95% confidence have not been reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Analysis: Time to Event-free Survival Event</title>
        <description>Event-free survival was defined as the time between randomization and the date of disease progression, relapse, start of new Chronic Lymphocytic Leukemia treatment or death by any cause.</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Participants from the Intent-to-treat population, that included all randomized participants, with disease progression, relapse, start of new Chronic Lymphocytic Leukemia treatment or death.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Time to Event-free Survival Event</title>
          <description>Event-free survival was defined as the time between randomization and the date of disease progression, relapse, start of new Chronic Lymphocytic Leukemia treatment or death by any cause.</description>
          <population>Participants from the Intent-to-treat population, that included all randomized participants, with disease progression, relapse, start of new Chronic Lymphocytic Leukemia treatment or death.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951.0" lower_limit="843" upper_limit="1039"/>
                    <measurement group_id="O2" value="1666.0" lower_limit="1415" upper_limit="1799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)</title>
        <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Participants from the Intent-to-treat population, all randomized participants, with complete response who experienced a disease free survival event (disease relapse or death).</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)</title>
          <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. DFS was calculated from time of CR to relapse or death</description>
          <population>Participants from the Intent-to-treat population, all randomized participants, with complete response who experienced a disease free survival event (disease relapse or death).</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1488.0" lower_limit="1198" upper_limit="1836"/>
                    <measurement group_id="O2" value="1854.0" lower_limit="1646" upper_limit="2208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0523</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Analysis: Duration of Response</title>
        <description>Duration of response was defined as the time from the first documented Complete Response, Partial Response to disease progression or death by any cause.</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Participants from the Intent-to-treat population, all randomized participants, with complete response or partial response who experienced an event (disease progression or death due to any cause).</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Duration of Response</title>
          <description>Duration of response was defined as the time from the first documented Complete Response, Partial Response to disease progression or death by any cause.</description>
          <population>Participants from the Intent-to-treat population, all randomized participants, with complete response or partial response who experienced an event (disease progression or death due to any cause).</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1102.0" lower_limit="977" upper_limit="1249"/>
                    <measurement group_id="O2" value="1718.0" lower_limit="1618" upper_limit="1859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response</title>
        <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. Partial response is defined as a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response</title>
          <description>CR is defined by at least 8 weeks of: 1)Absence of lymphadenopathy 2)No hepatomegaly or splenomegaly 3)Absence of B-symptoms 4)Normal blood count 5)Bone marrow aspirate and biopsy 8 weeks after the clinical and laboratory results demonstrated that a CR was achieved. A marrow sample had to be normocellular for age with less than 30% lymphocytes. Lymphoid nodules had to be absent. If marrow was hypocellular,a repeat biopsy was taken 4 weeks later and samples were re-reviewed in conjunction with the prior pathology. Partial response is defined as a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" lower_limit="67.8" upper_limit="76.7"/>
                    <measurement group_id="O2" value="85.8" lower_limit="82.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.62</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL)</title>
        <description>The time from randomization to the start of a new treatment.</description>
        <time_frame>Median observation time was approximately 66.4 months</time_frame>
        <population>Participants from the Intent-to-treat population, that included all randomized participants, who started a new CLL treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine+Cyclophosphamide (FC)</title>
            <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
            <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL)</title>
          <description>The time from randomization to the start of a new treatment.</description>
          <population>Participants from the Intent-to-treat population, that included all randomized participants, who started a new CLL treatment.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1455.0" lower_limit="1324" upper_limit="1577"/>
                    <measurement group_id="O2" value="2082.0" lower_limit="1926" upper_limit="2253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were recorded until 28 days after completion of study treatment (median time approximately 21 months). Serious Adverse Events reported until 1 year post-treatment or initiation of new CLL treatment (median time approximately 42 months).</time_frame>
      <desc>The safety population included all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine+Cyclophosphamide (FC)</title>
          <description>Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV on Days 1, 2, 3 for 6 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Fludarabine+Cyclophosphamide+Rituximab (FCR)</title>
          <description>Rituximab intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: 375 mg/mÂ² IV on Day 0; Cycles 2-6: 500 mg/mÂ² IV on Day 1. FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/mÂ² IV over 15-30 min on Days 1, 2, 3 for 6 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Febrile Bone Marrow Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Coombs Positive Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Evans Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Haematotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Supraventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Amaurosis Fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dacryostenosis Acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Abdominal Symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia, Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tongue Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>General Symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Ill-Defined Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hepatic Siderosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cytokine Release Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jiroveci Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jiroveci Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia Primary Atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cerebral Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia Fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Enterococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Cryptosporidial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hepatobiliary Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Herpes Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lung Infection Pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Oesophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia Respiratory Syncytial Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pseudomonal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Catheterisation Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumour Lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lung Squamous Cell Carcinoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Central Nervous System Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Histiocytosis Haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hodgkin's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lymphoma Transformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pharyngeal Cancer Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Skin Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Optic Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Alveolitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dyspnoea at Rest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Laryngeal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiration Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pustular Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Coronary Revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Haemorrhoid Operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vasculitis Necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="398"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

